These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24089460)

  • 1. Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants.
    Mir MC; Stephenson AJ; Grubb RL; Black A; Kibel AS; Izmirlian G
    Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2241-9. PubMed ID: 24089460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.
    Lotan Y; Karam JA; Shariat SF; Gupta A; Roupret M; Bensalah K; Margulis V
    Urol Oncol; 2016 Apr; 34(4):167.e9-16. PubMed ID: 26602092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort.
    Krabbe LM; Svatek RS; Shariat SF; Messing E; Lotan Y
    Urol Oncol; 2015 Feb; 33(2):65.e19-25. PubMed ID: 25044253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary fiber intake and the risk of bladder cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cohort.
    Luo J; Xu X
    Carcinogenesis; 2020 Jun; 41(4):478-482. PubMed ID: 31872237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Nonadherence to Cancer Screening Examinations With Mortality From Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial.
    Pierre-Victor D; Pinsky PF
    JAMA Intern Med; 2019 Feb; 179(2):196-203. PubMed ID: 30592477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
    Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
    J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation.
    Tammemagi CM; Pinsky PF; Caporaso NE; Kvale PA; Hocking WG; Church TR; Riley TL; Commins J; Oken MM; Berg CD; Prorok PC
    J Natl Cancer Inst; 2011 Jul; 103(13):1058-68. PubMed ID: 21606442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary carbohydrate, glycemic index, glycemic load, and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort.
    Shikany JM; Flood AP; Kitahara CM; Hsing AW; Meyer TE; Willcox BJ; Redden DT; Ziegler RG
    Cancer Causes Control; 2011 Jul; 22(7):995-1002. PubMed ID: 21553078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Pinsky PF; Miller A; Kramer BS; Church T; Reding D; Prorok P; Gelmann E; Schoen RE; Buys S; Hayes RB; Berg CD
    Am J Epidemiol; 2007 Apr; 165(8):874-81. PubMed ID: 17244633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk-stratified screening and colorectal cancer incidence and mortality: A retrospective study from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Zhang Y; Sheng C; Fan Z; Liu Y; Liu X; Duan H; Dai H; Lyu Z; Yang L; Song F; Song F; Huang Y; Chen K
    Prev Med; 2024 Oct; 187():108117. PubMed ID: 39178994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective investigation of body mass index, colorectal adenoma, and colorectal cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Kitahara CM; Berndt SI; de González AB; Coleman HG; Schoen RE; Hayes RB; Huang WY
    J Clin Oncol; 2013 Jul; 31(19):2450-9. PubMed ID: 23715565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Hocking WG; Hu P; Oken MM; Winslow SD; Kvale PA; Prorok PC; Ragard LR; Commins J; Lynch DA; Andriole GL; Buys SS; Fouad MN; Fuhrman CR; Isaacs C; Yokochi LA; Riley TL; Pinsky PF; Gohagan JK; Berg CD;
    J Natl Cancer Inst; 2010 May; 102(10):722-31. PubMed ID: 20442215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-Lowering Drug Use and Cancer Incidence and Mortality in the ARIC Study.
    Marrone MT; Mondul AM; Prizment AE; Couper D; Barber JR; Chappidi MR; Joshu CE; Platz EA
    JNCI Cancer Spectr; 2021 Oct; 5(5):. PubMed ID: 34738072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort.
    Kawakita D; Lee YA; Gren LH; Buys SS; La Vecchia C; Hashibe M
    Br J Cancer; 2018 Jan; 118(2):299-306. PubMed ID: 29161239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Pinsky PF; Ford M; Gamito E; Higgins D; Jenkins V; Lamerato L; Tenorio S; Marcus PM; Gohagan JK
    J Natl Med Assoc; 2008 Mar; 100(3):291-8. PubMed ID: 18390022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities.
    Laiyemo AO; Doubeni C; Pinsky PF; Doria-Rose VP; Bresalier R; Lamerato LE; Crawford ED; Kvale P; Fouad M; Hickey T; Riley T; Weissfeld J; Schoen RE; Marcus PM; Prorok PC; Berg CD
    J Natl Cancer Inst; 2010 Apr; 102(8):538-46. PubMed ID: 20357245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.
    Tsodikov A; Gulati R; Heijnsdijk EAM; Pinsky PF; Moss SM; Qiu S; de Carvalho TM; Hugosson J; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; Feuer EJ; de Koning HJ; Mariotto AB; Etzioni R
    Ann Intern Med; 2017 Oct; 167(7):449-455. PubMed ID: 28869989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to the Diabetes Risk Reduction Diet and Bladder Cancer Risk in the Prostate, Lung, Colorectal, Ovarian (PLCO) Cohort.
    Chen Y; Zeng S; Jiao B; Zhang H; Li G; Zhang X; Hu X
    Cancer Epidemiol Biomarkers Prev; 2023 Dec; 32(12):1726-1733. PubMed ID: 37721479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Barry SA; Tammemagi MC; Penek S; Kassan EC; Dorfman CS; Riley TL; Commin J; Taylor KL
    J Natl Cancer Inst; 2012 Nov; 104(21):1647-59. PubMed ID: 23104210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.